Abstract
Tamoxifen has long been an established adjuvant treatment in the management of advanced breast cancer. Studies carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and other groups also established its use in the treatment of early breast cancer and subsequently as a risk-reducing agent for the development of contralateral breast cancer in breast cancer patients. The NSABP began its investigation of tamoxifen as a preventive agent in the early 1990s in women who had never had the disease with its Breast Cancer Prevention Trial (P-1). Its second prevention study, the STAR trial, is currently under way.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee (1987) Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171–175
Costantino JP, Gail MH, Pee D, et al (1999) Validation studies for models to project the risk of invasive and total breast cancer incidence. J Nat! Cancer Inst 91:1541–1548
CRC Adjuvant Breast Trial Working Party (1988) Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604–607
Cummings SR, Eckert S, Krueger KA, et al (1999) The effects of raloxifene on the risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281:2189–2197
Fisher B, Brown A, Wolmark N, et al (1987) Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Int Med 106:649–654
Fisher B, Redmond C (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent [editorial). J Natl Cancer Inst 83:1278–1280
Fisher B, Costantino JP, Wickerham DL, et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l study. J Natl Cancer Inst 18:1371–1388
Fisher B, Dignam J, Wolmark N, et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000
Fisher B, Dignam J. Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690
Gail MH, Brinton LA, Byar DP, et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886
Gail MH, Costantino JP, Bryant J, et al (1999) Weighing the risk and benefits of tamoxifen for preventing breast cancer. J Natl Cancer Inst 91:1829–1846
Gorin MB, Day R, Costantino JP, et al (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125:493–501
Powles T, Eeles R, Ashley S, et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101
Reis SE, Costantino JP, Wickerham DL, et al (2001) Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. J Natl Cancer Inst 93:16–21
Rutqvist LE, Cedermark B, Glas U, et al (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299–1306
Tan-Chiu E, Costantino J, Wang J, et al (2001) The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). Proc Ann San Antonio Breast Cancer Symposium 69:210
Veronesi U, Maisonneuve P, Costa A, et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93–97
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wickerham, D.L. (2003). Tamoxifen’s Impact as a Preventive Agent in Clinical Practice and an Update on the STAR Trial. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics. Recent Results in Cancer Research, vol 163. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55647-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-55647-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62892-4
Online ISBN: 978-3-642-55647-0
eBook Packages: Springer Book Archive